We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Aro Biotherapeutics Stock

Invest in or calculate the value of your shares in Aro Biotherapeutics or other pre-IPO companies through EquityZen's platform.

Get Started

Aro Biotherapeutics Stock (AROB)

Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines.

About Aro Biotherapeutics Stock

Founded

2017

Headquarters

Philadelphia, PA, US

Industries

Software, Artificial Intelligence, Data and Analytics

Aro Biotherapeutics is focused on the development of a new protein drug platform called Centyrins, designed to achieve better efficacy and safety profiles for patients with cancer and other serious diseases. Centyrins are small, non-antibody protein scaffolds that can be expressed as multi-specifics with novel therapeutic mechanisms of action. Centyrins are also ideal for the targeted delivery of complex drug payloads, including nucleic acids.

Aro Biotherapeutics Press Mentions

Stay in the know about the latest news on Aro Biotherapeutics

Aro Biotherapeutics Management

Leadership team at Aro Biotherapeutics

Co-founder and Chief Scientific Officer

Karyn O’Neil

Co-founder, President and Chief Executive Officer

Susan Dillon

Locked Features

Join now and verify your accreditation status to gain access to:

  • Aro Biotherapeutics current valuation
  • Aro Biotherapeutics stock price
  • Available deals in Aro Biotherapeutics and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Aro Biotherapeutics stock?

Accredited investors can buy pre-IPO stock in companies like Aro Biotherapeutics through EquityZen funds. These investments are made available by existing Aro Biotherapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Aro Biotherapeutics stock?

Shareholders can sell their Aro Biotherapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."